A plasticized nylon and a medical device including plasticized nylon. The medical device may be a dilatation balloon. Also disclosed are methods of plasticizing nylon.

A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.

A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.

A material includes nonwoven fibers and a surface modification that crosslinks the nonwoven fibers together. The surface modification can include chemical reactive groups. The reactive groups can be selected from diisocyanates, alcohols, epoxides, imides, amides, imines, amines, diacrylates, disiloxanes and disilazanes. A method of forming the material electrospins fiber material in the form of fibers into a nonwoven material. A surface modification is introduced to the fibers either by modifying the fiber material before the electrospinning or by modifying the fiber surface after the electrospinning. The fibers are crosslinked to form the crosslinked nonwoven material.

A material includes nonwoven fibers and a surface modification that crosslinks the nonwoven fibers together. The surface modification can include chemical reactive groups. The reactive groups can be selected from diisocyanates, alcohols, epoxides, imides, amides, imines, amines, diacrylates, disiloxanes and disilazanes. A method of forming the material electrospins fiber material in the form of fibers into a nonwoven material. A surface modification is introduced to the fibers either by modifying the fiber material before the electrospinning or by modifying the fiber surface after the electrospinning. The fibers are crosslinked to form the crosslinked nonwoven material.

Provided herein are methods, compositions, devices, and systems for the 3D printing of biomedical implants. In particular, methods and systems are provided for 3D printing of biomedical devices (e.g., endovascular stents) using photo-curable biomaterial inks (e.g., or methacrylated poly(diol citrate)).

Provided herein are methods, compositions, devices, and systems for the 3D printing of biomedical implants. In particular, methods and systems are provided for 3D printing of biomedical devices (e.g., endovascular stents) using photo-curable biomaterial inks (e.g., or methacrylated poly(diol citrate)).

An intraluminal endoprosthesis has a biodegradable metallic supporting structure and a biodegradable sleeve surrounding the supporting structure. The sleeve includes fibres applied to the outer side of the supporting structure. The sleeve can be formed from fibres that each have a polymer core and a hydrogel casing. The sleeve can the sleeve be formed from a fibre mixture of polymer fibres and hydrogel fibres.

An intraluminal endoprosthesis has a biodegradable metallic supporting structure and a biodegradable sleeve surrounding the supporting structure. The sleeve includes fibres applied to the outer side of the supporting structure. The sleeve can be formed from fibres that each have a polymer core and a hydrogel casing. The sleeve can the sleeve be formed from a fibre mixture of polymer fibres and hydrogel fibres.

A composition, comprising: a physiologically-acceptable polydimethylsiloxane having a surface; and one or more normal C.sub.6-C.sub.20NR.sub.1R.sub.2 saturated amine, salt thereof, or combination thereof, in contact with the polydimethylsiloxane, the surface, or both, wherein R.sub.1 and R.sub.2 may be same or different and independently selected from H, —CH.sub.3, —CH.sub.2CH.sub.3, —CH.sub.2CH.sub.2CH.sub.3, or combination thereof.